From the Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts (Dr Louis); the Department of Pathology, Amsterdam Universities Medical Center/VUmc CCA Brain Tumor Center, Amsterdam, the Netherlands (Dr Wesseling); he Department of Pathology, Princess Máxima Center for Pediatric Oncology, and University Medical Center Utrecht, Utrecht, the Netherlands (Dr Wesseling); Division of Neuropathology, The National Hospital for Neurology and Neurosurgery, University College London NHS Foundation Trust, London, United Kingdom (Dr Brandner); the Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, United Kingdom (Dr Brandner); the Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois (Dr Brat); the Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee (Dr Ellison); the Department of Radiology, Oncology and Anatomic Pathology, University La Sapienza, Rome, Italy (Dr Giangaspero); RCCS Neuromed, Pozzilli, Isernia, Italy (Dr Giangaspero); the Department of Pathology, University of Louisville School of Medicine, Louisville, Kentucky (Dr Hattab); the Department of Laboratory Medicine & Pathobiology, The Hospital for Sick Children, Toronto, Ontario, Canada (Dr Hawkins); Project Management Office, Royal College of Pathologists of Australasia, Sydney, Australia (Ms Judge);he Departments of Pathology, Neurology, and Neurosurgery, University of Colorado, Aurora (Dr Kleinschmidt-DeMasters); the Department of Laboratory Medicine and Pathology (Neuropathology), Tokyo Metropolitan Neurological Hospital, Tokyo, Japan (Dr Komori); the Department of Pathology, Tokyo Women's Medical University School of Medicine, Tokyo, Japan (Dr Komori); Alfred Anatomical Pathology and NNF, Victorian Brain Bank, Carlton, Victoria, Australia (Dr McLean); Institute of Neuropathology, University Hospital Münster, Münster, Germany (Dr Paulus); Division of Neuropathology, Department of Pathology, University of California, San Francisco (Dr Perry); the Department of Neuropathology, Heinrich Heine University, Düsseldorf, Germany (Dr Reifenberger); German Cancer Consortium (DKTK), Partner Site Essen/Düsseldorf, Düsseldorf, Germany (Dr Reifenberger); the Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland (Dr Weller); and the Department of Histopathology, Addenbrookes Hospital, Cambridge, United Kingdom (Dr Rous); ICCR Steering Group Representative (Dr Rous).
Arch Pathol Lab Med. 2020 Feb;144(2):196-206. doi: 10.5858/arpa.2018-0565-OA. Epub 2019 Jun 20.
CONTEXT.—: Standards for pathology reporting of cancer are foundational to national and international benchmarking, epidemiology, and clinical trials, with international standards for pathology reporting of cancer being undertaken through the International Collaboration on Cancer Reporting (ICCR).
OBJECTIVE.—: To develop standardized templates for brain tumor diagnostic pathology reporting.
DESIGN.—: As a response to the 2016 updated 4th edition of the (World Health Organization) (2016 CNS WHO), an expert ICCR committee developed data sets to facilitate reporting of brain tumors that are classified histologically and molecularly by the 2016 CNS WHO; as such, this represents the first combined histologic and molecular ICCR data set, and required a novel approach with 3 highly related data sets that should be used in an integrated manner.
RESULTS.—: The current article and accompanying ICCR Web site describe reporting data sets for central nervous system tumors in the hope that they provide easy-to-use and highly reproducible means to issue diagnostic reports in consort with the 2016 CNS WHO.
CONCLUSIONS.—: The consistent use of these templates will undoubtedly prove useful for patient care, clinical trials, epidemiologic studies, and monitoring of neuro-oncologic care around the world.
癌症病理报告的标准是国家和国际基准、流行病学和临床试验的基础,癌症病理报告的国际标准通过国际癌症报告合作组织(ICCR)进行。
制定脑肿瘤诊断病理学报告的标准化模板。
作为对 2016 年更新的第 4 版(世界卫生组织)(2016 年 CNS WHO)的回应,一个专家 ICCR 委员会开发了数据集,以促进通过 2016 年 CNS WHO 进行组织学和分子分类的脑肿瘤报告;因此,这代表了第一个联合组织学和分子 ICCR 数据集,需要一种新颖的方法,使用 3 个高度相关的数据集,以综合的方式使用。
本文和随附的 ICCR 网站描述了中枢神经系统肿瘤的报告数据集,希望它们为与 2016 年 CNS WHO 一致发布诊断报告提供易于使用且高度可重复的方法。
这些模板的一致使用无疑将证明对全球范围内的患者护理、临床试验、流行病学研究和神经肿瘤护理监测有用。